18,878 Shares in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new position in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 18,878 shares of the company’s stock, valued at approximately $1,256,000.

A number of other hedge funds have also made changes to their positions in the company. HighTower Advisors LLC grew its holdings in shares of Invesco Biotechnology & Genome ETF by 64.1% in the third quarter. HighTower Advisors LLC now owns 7,101 shares of the company’s stock valued at $494,000 after purchasing an additional 2,774 shares in the last quarter. Jane Street Group LLC purchased a new position in Invesco Biotechnology & Genome ETF in the 3rd quarter valued at approximately $295,000. Jones Financial Companies Lllp boosted its holdings in Invesco Biotechnology & Genome ETF by 52.9% in the fourth quarter. Jones Financial Companies Lllp now owns 2,315 shares of the company’s stock valued at $154,000 after purchasing an additional 801 shares during the period. Massachusetts Wealth Management boosted its holdings in Invesco Biotechnology & Genome ETF by 1.3% in the fourth quarter. Massachusetts Wealth Management now owns 18,414 shares of the company’s stock valued at $1,225,000 after purchasing an additional 230 shares during the period. Finally, IHT Wealth Management LLC increased its holdings in Invesco Biotechnology & Genome ETF by 14.7% during the 3rd quarter. IHT Wealth Management LLC now owns 12,124 shares of the company’s stock worth $847,000 after purchasing an additional 1,550 shares during the period.

Invesco Biotechnology & Genome ETF Stock Up 1.9 %

Shares of Invesco Biotechnology & Genome ETF stock opened at $63.30 on Thursday. Invesco Biotechnology & Genome ETF has a 52-week low of $59.32 and a 52-week high of $72.84. The company has a 50 day moving average of $66.90 and a 200 day moving average of $68.24. The company has a market capitalization of $229.78 million, a P/E ratio of 23.00 and a beta of 0.80.

Invesco Biotechnology & Genome ETF Increases Dividend

The firm also recently disclosed a dividend, which was paid on Friday, March 28th. Stockholders of record on Monday, March 24th were given a dividend of $0.0341 per share. This is a boost from Invesco Biotechnology & Genome ETF’s previous dividend of $0.01. The ex-dividend date was Monday, March 24th.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.